Antiplatelet therapy in Takotsubo cardiomyopathy: does it improve cardiovascular outcomes during index event?
Plasma catecholamines may play an important role in Takotsubo cardiomyopathy (TCM) pathophysiology. Patients with disproportionately high catecholamine responses to stressful events are prone to worse clinical outcomes. Catecholamines stimulate platelet activation and, therefore, may determine the clinical presentation and outcomes of TCM. We conducted a retrospective, descriptive study TCM patients admitted between 2003 and 2013 to Einstein Medical Center, Philadelphia, PA, USA and Danbury Hospital, Danbury, CT, USA. A total of 206 patients met Modified Mayo TCM criteria. Using a multiple logistic model, we tested whether aspirin, dual antiplatelet therapy (DAPT) aspirin + clopidogrel, beta blocker, statin, or ACE inhibitor use were independent predictors of major adverse cardiovascular events (MACE) during the index hospitalization. MACE was defined as in-hospital heart failure, in-hospital death, stroke or respiratory failure requiring mechanical ventilation. Incidence of in-hospital heart failure was 26.7 %, in-hospital death was 7.3 %, stroke was 7.3 % and MACE was 42.3 %. In a multiple logistic regression model (adjusted for gender, race, age, physical stressor, hypertension, diabetes, hyperlipidemia, smoking history, body mass index, initial left ventricular ejection fraction, single antiplatelet therapy, DAPT, beta blocker, statin, and ACE inhibitor) aspirin and DAPT at the time of hospitalization were independent predictors of a lower incidence of MACE during the index hospitalization (aspirin: OR 0.4, 95 % CI (0.16-0.9), P = 0.04; DAPT: OR 0.23; 95 % CI (0.1-0.55); P < 0.01. Physical stressor itself was also found to be an independent predictor of worse MACE: OR 5.1; 95 % CI (2.4-11.5); P < 0.01. In our study, aspirin and DAPT were independent predictors of a lower incidence of MACE during hospitalization for TCM. Prospective clinical trials are needed to confirm the findings of this study.
Department of Cardiology, Einstein Medical Center, 5501 Old York Road, Philadelphia, PA, 19141, USA. andremacdias@gmail.com.|Western Connecticut Health Network, Danbury, CT, USA. andremacdias@gmail.com.
Andre
A
Dias
Department of Cardiology, Einstein Medical Center, 5501 Old York Road, Philadelphia, PA, 19141, USA.|Western Connecticut Health Network, Danbury, CT, USA.
Emiliana
E
Franco
Department of Medicine, Einstein Medical Center, Philadelphia, PA, USA.
Nikoloz
N
Koshkelashvili
Department of Cardiology, Einstein Medical Center, 5501 Old York Road, Philadelphia, PA, 19141, USA.
Vikas
V
Bhalla
Department of Cardiology, Einstein Medical Center, 5501 Old York Road, Philadelphia, PA, 19141, USA.
Gregg S
GS
Pressman
Department of Cardiology, University of Miami, Miami, FL, USA.
Kathy
K
Hebert
Department of Cardiology, Einstein Medical Center, 5501 Old York Road, Philadelphia, PA, 19141, USA.|Sidney Kimmel College of Medicine at Thomas Jefferson University, Philadelphia, PA, USA.
Vincent M
VM
Figueredo
D000368:Aged; D001241:Aspirin / Q000008:administration & dosage*; D000077144:Clopidogrel; D004359:Drug Therapy, Combination; D005260:Female; D006333:Heart Failure / Q000453:epidemiology*; D017052:Hospital Mortality; D006801:Humans; D007902:Length of Stay; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D012189:Retrospective Studies; D012720:Severity of Illness Index; D020521:Stroke / Q000453:epidemiology*; D054549:Takotsubo Cardiomyopathy / Q000150:complications* / Q000188:drug therapy*; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D016896:Treatment Outcome
D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin
Antiplatelets; Cardiovascular outcomes; Takotsubo cardiomyopathy